• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝门部胆管癌手术:保留肝实质肝切除术的可行性及结果

Surgery for hilar cholangiocarcinoma: feasibility and results of parenchyma-conserving liver resection.

作者信息

Ramesh Hariharan, Kuruvilla Kuruvilla, Venugopal Ambadi, Lekha Vijayalakshmi, Jacob George

机构信息

Department of Gastrointestinal Surgery, PVS Memorial Hospital, Cochin, India.

出版信息

Dig Surg. 2004;21(2):114-22. doi: 10.1159/000077335. Epub 2004 Mar 15.

DOI:10.1159/000077335
PMID:15024176
Abstract

BACKGROUND/AIM: Major liver resection has improved the resectability rate of hilar cholangiocarcinomas, but morbidity and mortality may be significant. The aim of this study was to assess the value of parenchyma-conserving liver resection (resection of bile duct with liver segments I and IVb; PCLR) in hilar cholangiocarcinoma.

METHODS

Retrospective analysis of prospectively collected data. Factors influencing survival following three types of operations were studied by univariate and multivariate analyses. The three types of operations were: (1) local resection of the bile duct alone (LR); (2) major liver resection (resection of three or more segments, hepatic resection; HR), and (3) PCLR.

RESULTS

Forty-six patients (21 males, 25 females; age range 35-77 years, mean age 57, median age 57 years) underwent surgery. There were 11 LR, 12 HR, and 23 PCLR procedures. There were 3 deaths (mortality 6.5%). The mortality was higher following HR (3 out of 12; 25%) than following LR or PCLR (0 out of 34; p = 0.01). Survival was longer following curative resection (median 27 months) than after palliative resection (median 15 months; p = 0.001). Lymph nodal and perineural involvement were adverse factors on univariate, but not on multivariate analysis. PCLR produced better survival (median 29 months) as compared with LR (median 15 months) or HR (median 22.5 months; p < 0.01).

CONCLUSIONS

PCLR is applicable to selected patients with Bismuth-Corlette type III disease without major vascular involvement and produces survival rates comparable to those of LR and HR. PCLR may help avoid major liver resections in some patients with hilar cholangiocarcinoma.

摘要

背景/目的:扩大肝切除术提高了肝门部胆管癌的切除率,但手术的发病率和死亡率可能较高。本研究旨在评估保留肝实质的肝切除术(联合肝段Ⅰ和Ⅳb切除胆管;PCLR)在肝门部胆管癌中的价值。

方法

对前瞻性收集的数据进行回顾性分析。通过单因素和多因素分析研究三种手术方式后影响生存的因素。三种手术方式为:(1)单纯胆管局部切除术(LR);(2)扩大肝切除术(切除三个或更多肝段,肝切除术;HR),以及(3)PCLR。

结果

46例患者(男性21例,女性25例;年龄范围35 - 77岁,平均年龄57岁,中位年龄57岁)接受了手术。LR手术11例,HR手术12例,PCLR手术23例。有3例死亡(死亡率6.5%)。HR术后死亡率(12例中有3例;25%)高于LR或PCLR术后(34例中0例;p = 0.01)。根治性切除术后生存时间更长(中位27个月),优于姑息性切除术后(中位15个月;p = 0.001)。单因素分析显示淋巴结和神经周围侵犯是不良因素,但多因素分析未显示。与LR(中位15个月)或HR(中位22.5个月)相比,PCLR的生存情况更好(中位29个月;p < 0.01)。

结论

PCLR适用于部分未累及主要血管的Bismuth - CorletteⅢ型疾病患者,其生存率与LR和HR相当。PCLR可能有助于避免部分肝门部胆管癌患者进行扩大肝切除术。

相似文献

1
Surgery for hilar cholangiocarcinoma: feasibility and results of parenchyma-conserving liver resection.肝门部胆管癌手术:保留肝实质肝切除术的可行性及结果
Dig Surg. 2004;21(2):114-22. doi: 10.1159/000077335. Epub 2004 Mar 15.
2
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.肝门部胆管癌切除术:同期肝切除可降低肝内复发率。
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
3
[Prognostic factors and long term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis].[肝门部胆管癌手术后的预后因素及长期结果。单因素和多因素分析]
Chir Ital. 2004 Nov-Dec;56(6):749-59.
4
[Partial hepatectomy with skeletonization of the hepatoduodenal ligament for hilar cholangiocarcinoma].[肝十二指肠韧带骨骼化的肝门胆管癌根治性肝切除术]
Zhonghua Wai Ke Za Zhi. 2004 Feb 22;42(4):210-2.
5
Extent of liver resection for hilar cholangiocarcinoma.肝门部胆管癌的肝切除范围。
Br J Surg. 2009 Oct;96(10):1167-75. doi: 10.1002/bjs.6618.
6
[Hepatectomy (parenchyma-preserving) for hilar cholangiocarcinoma].[肝门部胆管癌的(保留肝实质的)肝切除术]
Nihon Geka Gakkai Zasshi. 2000 May;101(5):413-7.
7
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
8
Application of portal parenchyma-enterostomy after high hilar resection for Bismuth type IV hilar cholangiocarcinoma.门静脉周围实质-肠吻合术在Bismuth Ⅳ型肝门部胆管癌高位肝门切除术后的应用
Am Surg. 2010 Feb;76(2):182-7.
9
[Minor liver resection for hilar cholangiocarcinoma of Bismuth-Corlette type III].[铋-柯莱特III型肝门部胆管癌的肝部分切除术]
Zhonghua Wai Ke Za Zhi. 2009 Aug 1;47(15):1148-50.
10
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience.肝门部胆管癌的积极手术切除:是否合理?单中心经验的审计
Am J Surg. 2008 Aug;196(2):160-9. doi: 10.1016/j.amjsurg.2007.07.033. Epub 2008 May 7.

引用本文的文献

1
Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients.肝门部胆管癌的微创手术:158例患者的多中心回顾性分析
Surg Endosc. 2021 Dec;35(12):6612-6622. doi: 10.1007/s00464-020-08161-8. Epub 2020 Nov 30.
2
Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure.肝门部胆管癌:旨在治愈的手术切除范围的争议
Int J Colorectal Dis. 2015 Feb;30(2):159-71. doi: 10.1007/s00384-014-2063-z. Epub 2014 Nov 8.
3
Rare distant skeletal muscle metastasis from hilar cholangiocarcinoma: report of a case.
肝门部胆管癌罕见的远处骨骼肌转移:一例报告
J Gastrointest Cancer. 2011 Sep;42(3):171-3. doi: 10.1007/s12029-010-9237-x.
4
Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.基于吉西他滨的辅助化疗可提高肝门部胆管癌根治性手术后的生存率。
J Gastrointest Surg. 2009 Aug;13(8):1470-9. doi: 10.1007/s11605-009-0900-0. Epub 2009 May 7.